Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK3 | P49761 | 11/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.54 |
| ▸ | CLK2 | P49760 | 10/20 | 0.54 |
| ▸ | ITK | Q08881 | 9/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29714863 | 1.00 | CLK3 (0.54) | CLK3DYRK1ACLK2ITK | |
| SCHEMBL29714867 | 0.89 | CLK2 (0.63) | CLK3DYRK1ACLK2ITK | |
| SCHEMBL18426815 | 0.89 | CLK2 (0.63) | CLK3DYRK1ACLK2ITK | |
| SCHEMBL2274785 | 0.86 | ITK (0.68) | CLK3DYRK1ACLK2ITK | |
| SCHEMBL29714858 | 0.86 | ITK (0.68) | CLK3DYRK1ACLK2ITK | |
| SCHEMBL16456187 | 0.84 | CLK3 (0.60) | CLK3DYRK1ACLK2 | |
| SCHEMBL18426827 | 0.83 | ITK (0.73) | CLK3DYRK1ACLK2ITK | |
| SCHEMBL18484423 | 0.82 | CLK2 (0.51) | CLK3DYRK1ACLK2ITK | |
| SCHEMBL20452886 | 0.82 | DYRK1A (0.56) | CLK3DYRK1ACLK2ITK | |
| SCHEMBL18426816 | 0.81 | CLK2 (0.60) | CLK3DYRK1ACLK2ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197523-A1 | MOTORIZED INJECTION SYSTEM AND METHODS OF USE | MEIRAGTX UK II LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-20180221352-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2018-08-09 | — | — | US | disclosed |
| US-20180221352-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2018-08-09 | — | — | US | disclosed |
| WO-2017023981-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023981-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221352-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | WNT1, WNT3A, WNT3 | CLK3 2160/4885DYRK1A 896/4885CLK2 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.